CN Patent

CN101511365A — 含特异内皮素受体拮抗剂和pde5抑制剂的治疗组合物

Assigned to Actelion Pharmaceuticals Ltd · Expires 2009-08-19 · 17y expired

What this patent protects

本发明关于一种产物，其含有右式(I)的化合物或此化合物的医药学上可接受的盐与至少一种具有PDE5抑制特性的化合物或其医药学上可接受的盐的组合，其在涉及血管收缩的疾病的治疗中同时地、个别地或历经一段时间地用于治疗用途。

USPTO Abstract

本发明关于一种产物，其含有右式(I)的化合物或此化合物的医药学上可接受的盐与至少一种具有PDE5抑制特性的化合物或其医药学上可接受的盐的组合，其在涉及血管收缩的疾病的治疗中同时地、个别地或历经一段时间地用于治疗用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN101511365A
Jurisdiction
CN
Classification
—
Expires
2009-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.